Proteomic profiling of plasma in Huntington's disease reveals neuroinflammatory activation and biomarker candidates.
Huntington's disease (HD) causes widespread CNS changes and systemic abnormalities including endocrine and immune dysfunction. HD biomarkers are needed to power clinical trials of potential treatments. We used multiplatform proteomic profiling to reveal plasma changes with HD progression. Proteins of interest were evaluated using immunoblotting and ELISA in plasma from 2 populations, CSF and R6/2 mice. The identified proteins demonstrate neuroinflammation in HD and warrant further investigation as possible biomarkers.
Dalrymple
Annette
A
Proteome Sciences PLC, Cobham, Surrey, United Kingdom.
Wild
Edward J
EJ
Joubert
Richard
R
Sathasivam
Kirupa
K
Björkqvist
Maria
M
Petersén
Asa
A
Jackson
Graham S
GS
Isaacs
Jeremy D
JD
Kristiansen
Mark
M
Bates
Gillian P
GP
Leavitt
Blair R
BR
Keir
Geoff
G
Ward
Malcolm
M
Tabrizi
Sarah J
SJ
D000818:Animals; D015415:Biomarkers / Q000097:blood; D001798:Blood Proteins / Q000032:analysis*; D015153:Blotting, Western; D002490:Central Nervous System / Q000378:metabolism*; D015180:Electrophoresis, Gel, Two-Dimensional; D004660:Encephalitis / Q000097:blood* / Q000276:immunology; D004797:Enzyme-Linked Immunosorbent Assay; D006801:Humans; D006816:Huntington Disease / Q000097:blood* / Q000276:immunology; D015850:Interleukin-6 / Q000097:blood; D051379:Mice; D040081:Protein Array Analysis; D040901:Proteomics
D015415:Biomarkers; D001798:Blood Proteins; D015850:Interleukin-6